We are live on ! Find out more
IRD

Opus Genetics
IRD

79 hedge funds and large institutions have $204M invested in Opus Genetics in 2026 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

367% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 6

265% more capital invested

Capital invested by funds: $55.9M → $204M (+$148M)

34% more funds holding

Funds holding: 59 → 79 (+20)

23.5% more ownership

Funds ownership: 40.33% → 63.83% (+23%)

7% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 15

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
79
Holders Change
+20
Holders Change %
+33.9%
% of All Funds
0.97%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
28
Increased
16
Reduced
15
Closed
6
Calls
$897K
Puts
–
Net Calls
+$897K
Net Calls Change
+$723K

Top Buyers

1
CP
Caligan Partners
New York
+$21M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$17M
3
BCM
Boxer Capital Management
California
+$7.78M
4
Marshall Wace
Marshall Wace
United Kingdom
+$7.46M
5
ACM
ADAR1 Capital Management
Texas
+$6.26M

Top Sellers

1
NCM
Nantahala Capital Management
Connecticut
-$10.7M
2
PA
Perceptive Advisors
New York
-$8.61M
3
MBAM
Mink Brook Asset Management
Florida
-$3.72M
4
VC
Voss Capital
Texas
-$888K
5
Wells Fargo
Wells Fargo
California
-$824K
Name Holding Trade Value Shares
Change 		Change in
Stake
CP
1
Caligan Partners
New York
$27.6M +$21M +6,075,028 New
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$27.4M +$17M +4,924,779 +446%
BCM
3
BIOS Capital Management
Texas
$16.8M – – –
Balyasny Asset Management
4
Balyasny Asset Management
Illinois
$12.4M – – –
Millennium Management
5
Millennium Management
New York
$12M +$2.17M +627,882 +31%
VCM
6
Vanguard Capital Management
Pennsylvania
$11.1M +$8.48M +2,449,987 New
Marshall Wace
7
Marshall Wace
United Kingdom
$10.5M +$7.46M +2,155,732 +1,367%
BCM
8
Boxer Capital Management
California
$10.2M +$7.78M +2,250,000 New
ACM
9
ADAR1 Capital Management
Texas
$8.41M +$6.26M +1,809,004 +4,523%
PA
10
Perceptive Advisors
New York
$8.35M -$8.61M -2,489,158 -58%
NCM
11
Nantahala Capital Management
Connecticut
$7.65M -$10.7M -3,100,000 -65%
WP
12
Woodline Partners
California
$6.16M +$4.68M +1,354,030 New
BFM
13
Boothbay Fund Management
New York
$5.41M +$4.11M +1,189,113 New
FCM
14
Farallon Capital Management
California
$4.55M +$3.46M +1,000,000 New
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$3.75M +$2.15M +621,748 +308%
BL
16
Bleichroeder LP
New York
$3.35M – – –
MBAM
17
Mink Brook Asset Management
Florida
$2.69M -$3.72M -1,075,079 -65%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$2.45M +$115K +33,364 +7%
TECP
19
Trails Edge Capital Partners
Georgia
$2.27M +$1.73M +500,000 New
OM
20
Opaleye Management
Massachusetts
$2.25M – – –
Ameriprise
21
Ameriprise
Minnesota
$1.77M +$1.34M +388,491 New
Goldman Sachs
22
Goldman Sachs
New York
$1.49M +$1.13M +326,809 New
GPP
23
Great Point Partners
Connecticut
$1.48M +$1.12M +324,340 New
VFT
24
Vanguard Fiduciary Trust
Pennsylvania
$1.28M +$975K +281,801 New
UBS Group
25
UBS Group
Switzerland
$1.17M +$581K +167,831 +187%
1
2 3 4

IRD Hedge Fund Activity: Q1 2026 in Review

79 of the 8,125 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q1 2026, worth a combined $204M — up 265% from $55.9M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new IRD positions and 6 closed out — a net gain of 22 holders — while 16 added to existing stakes and 15 trimmed.

The largest buyer was Caligan Partners, opening a new position worth an estimated $21M. The largest seller was Nantahala Capital Management, cutting an estimated $10.7M.

  • 79 institutional investors held Opus Genetics (IRD) as of Q1 2026, up from 59 in Q4 2025.
  • Funds reported $204M of Opus Genetics stock for Q1 2026, up 265% quarter-over-quarter.
  • 28 funds opened new Opus Genetics positions in Q1 2026 and 6 closed out, a net change of +22 holders.
  • The largest Opus Genetics buyer in Q1 2026 was Caligan Partners, an estimated $21M added.
  • The largest Opus Genetics seller in Q1 2026 was Nantahala Capital Management, an estimated $10.7M sold.

Based on aggregated 13F filings for Q1 2026.